Short-term Guidelines were given to assist physicians who are treating babies with influenza-like sickness while mired in a pandemic of H1N1. The approval was based on information garnered during the current public health crisis relating to the H1N1 pandemic situation and the high risk group of infants that remain susceptible from the influenza virus. This called for necessary measures produced by vital conditions.

There is currently limited knowledge that concerns the administering of Tamiflu in patients below one year of age; a critical requirement has come to pass where this part of the citizenry needs to be treated because of the rise in morbidity and mortality due to H1N1 influenza. The Health services communities in the United States as well as Great Britain have also made this recommendation to treat infants with antiviral medicine Tamiflu.

Physicians Wanted Leadership To Show The Way

The modification was a reflection of the necessity to look hard at concerns from primary health care providers who wanted the government to take a leadership role and make the hard decision to treat infants instead of them having to guess at treatment with tamiflu in an off label manner. The decision to finally treat very ill babies with Oseltamivir is a no brainer considering the alternative could be hospitalization, harsh illness courses and even death from H1N1 influenza infection. Weighed against not treating infants with a medication – Tamiflu – which has an excellent safety record when administered in proper dosages to adults and younger kids.

Health officials also stated that responsible family members or caretakers of these children should be notified that the medication is being administered under special circumstances. The medication can be used when an assumed infection of H1N1 influenza is verified with a quick and affirmative test outcome. In addition, if a child presents with hyperthermia and no other reason can be found, a past exposure to an infected person, likewise if there is a fever and breathing is distressed. The course of action calls for administering Tamiflu using dosages according to the child’s age and weight.

Zanamivir or [Relenza] is also approved in kids seven years of age or older. Though a case of Tamiflu resistance was confirmed in the past week in Canada, the drug had been administered as a prophylaxis to avoid illness. This individual only suffered mild sickness and completely improved. There was no indication that the resistant strain was transmitted.

Canadian health experts also recruited twelve ICU departments in various provinces to examine the cause of why certain H1N1 virus sufferers appear to get hit harder from the infection than some others do. They will also study the function of risk factors with rigorous illness like age, gender, weight, and immune deficiency. Also, research will be done to figure out the length of time that the seriously sick patients continue to be contagious and the best practices for dealing with severity in the illness.

Concerns And Unfavorable Effects in Children Taking Tamiflu?

When oseltamivir was researched during clinical trials for use in kids with influenza, the ones taking tamiflu had comparable adverse reactions as those kids not taking the tamiflu. There were no grim side effects recorded. The most frequent adverse reactions in treatment and preventive measure trials were nausea and vomiting. The clinical trials recorded an incidence of some children quitting their tamiflu because of the previously mentioned side effects.

A safety appraisal showed a few adverse incidents were recorded with the use of tamiflu on children sixteen years old and younger. The reports were mainly to do with unique neurological or psychiatric occurrences like delirium, delusion, confusion, strange behavior, encephalitis and seizures. These results were nearly all reported from Japan who were administered tamiflu using Japanese guidelines, which were similar though not equal to those in America.

There were twelve recorded fatalities in child patients since tamiflu was granted approval. Mortality figures were all documented as being child patients from Japan. Certain cases were clouded regarding tamiflu influence in the deaths since other medications were involved as well as other clinical health conditions not to mention a lack of sufficient information outlined in the data.

The evaluation also recorded harsh epidermis reactions similar to allergies in certain young patients. Not all of these cases were found in Japanese kids and this reaction has appeared in adults as well. These severe skin anomalies in every age bracket are now being studied more closely.

The use of tamiflu – oseltamivir antiviral medicine in children suspected of suffering from H1N1 is a double edged sword but not utilizing it for any sick patient regardless of age in a time of a pandemic illness would be poor judgment on the part of health experts. Parents can make a life or death determination with the best advice available regarding the use of Tamiflu in their infant children.

Swine Flu, Tamiflu

There are many flu viruses in the avian populations but the H5N1 infection is the most worrisome for health service officials for a couple reasons.

One, H5N1 infection has been responsible for the highest number of recorded cases of extremely virulent illness as well as the highest mortality rate. On three occasions it has jumped species to infect humans most recently in 2004 and our current trouble, but also in Hong Kong in 1997 when there were 18 infections and one third of them fatalities and also Hong Kong in 2003 with 2 cases and one death.

Two, and even more disconcerting is that the current H5N1 virus runs the risk of mutating, if enough chances are presented to it, into an infection of pandemic proportions. Thus far the H5N1 virus has displayed all the rudimentary qualities it needs to initiate a pandemic except one critical component, the capacity to be effectually transmitted from human to human. While currently the H1N1 virus is at the critical pandemic level, the potential for a pandemic to develop from a mutated human version of H5N1 virus must not be ignored.

The H5N1 virus can suddenly begin infecting people in two ways. The first is in an exchange process between viruses. The genetic matter is passed between a human and bird flu virus while there is a mutual infection of the two viruses with a person or a pig. This trade of material or shuffling process could mean the mutated result is a very dangerous and highly infectious pandemic virus and would be introduced into society by a rash of human cases and a rapid spread.

Another method would be slower but no less perilous, adaptive mutation is caused by the virus attaching to human cells in a steady manner through successive human infections and the virus becomes more capricious and pernicious as it gathers momentum forming small groups of human illness where there is confirmation of person to person contact. This second version of events would at least, if discovered early enough, give authorities some valuable time to respond.

In the Hong Kong H5N1 influenza spate of 1997, there were eighteen cases of illness which happened to take place when there was an outbreak of a far more severe and contagious bird flu by a virtually matching strain of the virus occurring on poultry farms and in public poultry markets. Intense follow up studies with familial and personal contacts of the patients, health care personnel, and those who culled flocks of birds determined there was little confirmation, in not any at all to confirm the spread between humans. In three days time, the culling of all poultry in Hong Kong ensured there was no further human infections. This at the expense of a million and a half birds that world medical officials credit with preventing a pandemic of avian influenza.

Everything up until now points to humans making contact with infected or dead birds as the primary source of illness in humans from H5N1 virus. People at risk are those who butcher, pluck feathers, initiate the bird kill process and those who process poultry meat for consumption when handling infected bird carcasses. Some individuals came into contact with chicken feces specifically using a poultry free range as a playground for kids and subsequently became ill. Experts also believe that swimming in water that contained dead bird cadavers or where infected birds could have contaminated with their droppings is potentially a further cause of some infections.

Not all cases of initial virus exposure could be indentified making authorities consider the possibility that some undiscovered infectivity factor with the virus may be the cause of certain cases. Some thoughts about what this cause may be area possible connection with feral birds such as pigeons or perhaps employing bird droppings as a form of fertilizer. For the time being H5N1 avian influenza is primarily a bird illness. The obstacle of single species strains of flu is noteworthy since the virus does not transfer from birds to humans without difficulty.

Notwithstanding the fact that there have been millions upon millions of diseased poultry in huge areas since the year 2003 there have only been less than a couple hundred cases of clinically diagnosed human H5N1 infection. There must be a reason, as yet not understood, why many of these infections occurred out in the country or semi rural locations where families and farmers maintain smaller stocks of poultry. It is also an anomaly that there are fewer infections in those groups that would ordinarily be considered at greater risk such as industrial poultry personnel, live poultry market vendors, those who cull flocks, veterinarians, health care workers who aid the patients that are ill, many not having the proper safety gear to do so without leaving them vulnerable.

There is also a lack of data or understanding of why kids who were in good health and medically fit young adults seemed to get ill. Health officials need to quickly discover logical reasons for this type of exposure. Are there certain behaviors involved? Perhaps there are immunity or genetic circumstances that seem to leave these groups vulnerable to infection?

Evaluating Potential infections in People

Examining many of the verified human infected with H5N1 virus, those in Asian nations and in Turkey, showed that direct contact with diseased avian species as presumably the primary reason for exposure. When reviewing likely infections, medical personnel should be inclined to look at those people displaying signs of influenza symptoms such as respiratory illness, hyperthermia etc. and those persons with a close proximity to birds. Particular attention should be paid to those presenting with these symptoms who reside in locations of verified outbreaks of the contagious H5N1 bird flu are active. If those presenting symptoms are from an environment where avian fecal matter may have caused contamination then than perhaps this would be a secondary consideration for exposure.

To this point, human infections of H5N1 virus are not all the responsibility of contact with diseased carcasses or tame bird stock that look like they are ill. In 2005 reports showed that domicile ducks could emit large amounts of high contagion virus but display none of the illness symptoms. There was no threat to people who ate poultry from these countries provided they cooked their poultry well and those people did not take part in prepping the food.

Since there is not a sign of any person to person spread of this virus anywhere, there is no discernable hazard for anyone travelling to these countries where outbreaks occur provided obvious precautions are taken such as staying away from open air poultry markets, farms or any other location where diseased bird contact is imminent or has occurred in the past.

How Clinical Symptoms Present

When a patient with H5N1 influenza becomes ill the infection is usually quite aggressive during its path, with patients displaying a fast decline with an elevated mortality. As with most new diseases, H5N1 influenza has a long learning curve for health officials. Health services data compiled in 1997 along with the latest epidemic are only now starting to illustrate the clinical characteristics of the infection yet there is so much left to study. Making matters worse is the fact that the virus has a habit of mutating quickly meaning its unpredictable nature makes disease mapping that much more frustrating for researchers.

The infection development phase for H5N1 avian flu is probably longer than the more common seasonal influenza which stand around two or three days. Any current information regarding disease incubation shows a range of two days to eight and quite probable extending to a length of seventeen days. But the Likelihood of numerous exposures to the H5N1 virus means accurately calculating a disease development period quite difficult. The WHO is currently saying clinicians should use a seven day gestation period in order to conduct examinations at ground zero for illness and when observing patient acquaintances.

The illness presents itself through elevated temperature, higher than 38° Celsius with influenza type indicators. Vomiting and diarrhea, stomach pain, chest pain and gum and nosebleeds have been cited as pre symptomatic signs with certain patients. Watery diarrhea with no blood seems more common in H5N1 than in the season variety of flu. The range of illness symptoms may be wider still. Verified patient illnesses have not all included respiratory problems.

Several Vietnamese persons infected the diagnosis was severe encephalitis: neither of these people showed any respiratory distress when they presented. Another infection in Thailand had the patient presenting with hyperthermia and diarrhea but no lung/breathing distress. In all three of these infected patients they had been in direct contact with diseased poultry.

A characteristic observed in a number of illnesses was the development of indicators in the lower respiratory tract in the beginning stages of the illness. Many patients display these lower respiratory symptoms when initially looking for treatment. Based on current knowledge, breathing irregularities begin to manifest about day five of the onset of illness. Respiratory trouble, hoarseness in the voice, and a discernable crackly noise while inhaling are most likely observed. Phlegm production is erratic and occasionally tainted with blood. Lately there have been bloody respiratory secretions seen in Turkey. Nearly all patients wind up with pneumonia.

Throughout the Hong Kong influenza illness spurt, the severely sick people showed primary viral pneumonia that antibiotics couldn’t help. Inadequate information about patients in the current outbreak show the signs of primary viral pneumonia in H5N1 that usually fail to show signs of bacterial supra-infection when determining diagnosis. Turkey medical officials have documented pneumonia as a consistent characteristic in more harsh cases, and the same as other patients, these people did not respond to being treated with antibiotics.

Those patients with H5N1 Influenza suffer a quick decline in their illness. There was a six day time period from the beginning of the flu to respiratory distress in Thai patients with an overall spectrum of four to thirteen days. Severe Turkish H5N1 illnesses the respiratory decline was three to five day after initial symptoms appeared according to medical experts. Something else which appears all too common is the irregular function of multiple organs. General laboratory anomalies, consisted of leukopenia (chiefly lymphopenia), mild-to-moderate thrombocytopenia, prominent aminotransferases, and with several occasions of disseminated intravascular coagulation.

There is some confirmation that particular antiviral medications, especially Oseltamivir or generic Tamiflu as it is known commercially, as they decrease the ability of the virus to reproduce thus improving the odds of survivability. They must be taken inside a forty eight hour window from the start of symptoms to be effectual. Data collected from the Turkish outbreak suggests that the majority of those with the virus were diagnosed and treated well into their course with the illness. It is because of this information that the use of Oseltamivir as a treatment is somewhat incomplete.

Oseltamivir or Tamiflu and other antiviral medications where produced as forms of treatment and as prophylaxis methods for seasonal variations of influenza, known to be a less severe version of flu as well as having a longer virus reproduction process in the body. The options for treatment courses and dosage quantities are still in a state of fluidity for oseltamivir – tamiflu therapeutic treatment of H5N1 influenza as it is with child illness of the virus. The WHO is continually monitoring and reviewing these antiviral practices as they require vital revision.

When a case of H5N1 influenza is suspected, generic tamiflu needs to be prescribed and taken as quickly as possible, preferably within forty eight hours from becoming symptomatic in order to optimize the value of the medication. Given the virulence of the current strain and the length of time of replication process, mortality rate etc. it would behoove the primary physician to begin treatment with generic Tamiflu also in those patients who are well into the illnesses course.

The existing suggested dosages for generic tamiflu for influenza virus treatments can be located on the Manufacturer – Roche’s website under product information. Currently the optional dose for generic tamiflu for influenza therapy is 150 mgs daily for children thirteen years and over and also adults, administered twice daily at 75 mg each for a course of five days minimum. There is no record of Tamiflu treatment for kids under one year old. The WHO health experts are looking into issuing treatment dosages and recommendations for children under the age of one year.

Since H5N1 viral reproduction periods could be extended, clinical personnel should reflect on increasing the tamiflu course treatment from five days up to seven or ten days in patients who are not responding to average treatment courses. When a patient displays severe H5N1 infection, they may want to raise the suggested daily dosage or length of treatment time. Clinicians also need to remember that Tamiflu dosages higher than 300 mg per day can be responsible for an increase in adverse effects . These same clinicians may want to consider administering serial clinical samples for future examination so viral loads can be monitored, an assessment can be made on medication susceptibility and levels of tamiflu can be reviewed. But, these samples should only be ingested where suitable procedures for infection control are available.

When a patient with H5N1 is suffering from a severe form of the illness and hampered by gastrointestinal symptoms, the absorption of Oseltamivir – Tamiflu could be hindered. Clinicians need to be cognizant of this prospect when treating patients such as these.

Bird Flu

The Message is clear that women who appear showing influenza type symptoms or illness need to be treated as quickly as possible. There shouldn’t be any waiting for a test result to verify the illness. There has been an update of the advice for preventative prophylactic treatment with antivirals in groups prone to risk [or chemoprophylaxis]. There have also been instructions updates for infant feeding that looks further into using masks and a requirement for a careful stance on stemming viral infection in infants though there is not much information to refer to. The recommendations are fluid based upon what is currently understood about the H1N1 viral spread within America and updates are planned as data becomes available.

The first known human infection with this strain of swine flu [the name was changed by the WHO to Novel influenza A H1N1 due to concerns over pork sales among other reasons] occurred in April 2009. The illness has been severe in pregnant women though the depth and transmission of this strain is under intense examination to better understand its effect on pregnant women and infants.

Though current information is not readily available, harkening back to past epidemics and pandemics is useful and available data for seasonal influenza and the effect on pregnant women is also being used in studies. There were an above average number of influenza linked fatalities in pregnant women throughout the Spanish influenza pandemic of 1918-1919 and the pandemic of Asian flu in 1957-1958. There have been unfavorable pregnancy results reported subsequent to prior influenza pandemics including miscarriage and premature births particularly in those women who contracted pneumonia.

Case studies and epidemiology reports carried out during pandemics past and interpandemic periods concluded that a women’s risk is greater during her pregnancy for complications related to influenza and there are signs of perinatal difficulties and delivery problems.

Women who become infected with the Novel influenza H1N1 strain of the infection it is predicted would have the normal respiratory illness seen in influenza cases presenting symptoms such as sore throat, runny nose, fever and cough. Perhaps accompanied by body aches, headaches, fatigue, diarrhea and vomiting and most pregnant women will proceed with a normal infliction of influenza without complication.

However, certain pregnant women will find the illness hitting harder and faster than others and possibly have secondary infections such as bacterial pneumonia. It’s during these difficult times for the mother that prenatal fetal distress caused by the maternal illness. There are reports of maternal fatalities as well as fetal complication outcomes linked to relentless illness. The ideal scenario would have the pregnant women being tested for influenza at an early symptomatic phase but delays in treatment for testing and awaiting those results are highly inadvisable since antiviral treatment are at their most effectual in the first forty eight hours of from the beginning of symptoms.

Testing will often take several days and may not be available at all for the Novel H1N1 though research is being undertaken vigorously to discover a rapid testing kit with great progress being made.

Primary health care providers need to be aware of the influenza outbreak in local areas of their practice and bypass the testing process in favor of treatment in those women who are pregnant and presenting symptoms of H1N1 influenza A illness.

Treatment and Chemoprophylaxis

Pregnant women who present with influenza like symptoms should undergo the earliest treatment possible with antiviral medications. Health care providers mustn’t wait for test results to come in to determine if influenza exists before starting treatment. Therapy should be initiated as soon as possible once symptoms begin to show for the best chance of success with these medications. The H1N1 influenza that is currently being transmitted has shown sensitivity to the neuraminidase inhibitor antiviral drugs zanamivir [Relenza®] and oseltamivir [Generic Tamiflu] but has built a resistance to adamantane antivirals amantadine [Symmetrel®] plus rimantadine [Flumadine®] .

Generic Tamiflu is an oral medication and the drug is absorbed systemically and the zanamivir is inhaled which lowers the systemic absorption somewhat. Tamiflu and Relenza as treatments and chemoprophylaxis course of therapies are suggested for women who are pregnant and are the same as if for an adult who is inflicted with seasonal influenza. In no way should a pregnancy be measured as a contraindication to tamiflu or Relenza usage. All indicators show pregnant women are more susceptible to harsh complications resulting from a bout with Novel H1N1 influenza A infection. They would benefit from a course of treatment or preventative therapy using Generic Tamiflu or Relenza, the risks outweighed by the antiviral use at this stage of infection in a pregnant women.

There have been some unfavorable reactions in those women who have ingested the antivirals generic tamiflu and Relenza though there has been no link between these adverse effects and actually taking generic tamiflu or relenza in pregnant women. It is recommended that health care providers stay up to date on CDC releases for the further use of generic tamiflu and relenza for H1N1 influenza A infection as the virus’ data is compiled over time so patients can further benefit.

Treatment Recommendations

Pregnant women showing flu like symptoms should have their medicinal therapy initiated before a firm diagnosis is confirmed. Because of its absorption process generic tamiflu is the drug treatment of choice and the treatment course recommended should last five days. There should not be any hold up of treatment while awaiting testing results since antiviral drugs for empirical use for anyone on this regimen need to be started within forty eight hours of the onset of influenza indicators being discovered. This therapy initiative is based on information collected from research conducted during seasonal influenza outbreaks.

This data also showed that there are benefits to those patients who are in hospital receiving the medication even after the forty eight hour time period so the antivirals are to be initiated for all high risk individuals who are symptomatic and in need of care whether or not the forty eight hour onset rule is exceeded, including pregnant women, persons with chronic illness and lowered immunity levels and those who require hospitalization.

Chemoprophylaxis Recommendations

Subsequent contact viral prophylactic use of medications like generic tamiflu and zanamivir should be judged useful for pregnant women who are confirmed or suspected of being infected with the Novel influenza A H1N1 virus. The medication most recommended for disease prevention or as a transmission inhibitor is likely zanamivir because of its partial systemic absorption properties. There could be certain problems associated with zanamivir usage because it is administered as an inhalant which may result in respiratory complications in women at risk of these ailments. Tamiflu then becomes the drug of choice for these patients.

The duration for this preventative treatment course is ten days after exposure to H1N1 virus was finally noticed. Pregnant women in multiple exposure situations to the virus in familial circumstances as an example, need to be monitored closely to determine the actual time period for preventative treatment depending on their medical situation and how it develops.

Hyperthermia [Fever] Treatment

One severe unpleasant symptom that affects influenza sufferers is the related hyperthermia or fever condition in a patient. Research has revealed that hyperthermia in pregnant women specifically in the first three months of pregnancy doubles the odds of having developmental problems with the fetal central nervous system or neural tube defects and could also be responsible for other birth defects and unfavorable birth results. Some research shows that hyperthermia related birth complications may be lessened by medications such as antipyretics or multivitamins such as folic acid which is highly recommended even for naturally progressing pregnancies.

Pregnancy related fever during labor constitutes further risks like developmental complications and neonatal problems such as seizures, cerebral palsy, encephalopathy and even neonatal fatality. Trying to determine the cause of a fevers effects from the fever itself is troubling so treatment of the hyperthermia is the first priority and Acetaminophen seems to be the choice option for fever control during a pregnancy.

The suggested dosages for antiviral drug treatment for novel influenza A H1N1 strain virus infections are as follows:

Tamiflu [Oseltamivir]

Adults should take 75 mg capsule twice daily for five days – 75 mg capsule once daily.

Zanamivir

Adults should inhale two 5 mg doses [10 mg total] twice daily for 5 days – Two 5 mg inhalations [10 mg total] once daily.

Other Ways To Reduce Risk For Pregnant Women

Currently there is not a vaccine available for the prevention of influenza A H1N1 infection though medical researchers are working feverishly to develop a potent anti virus vaccine. Therefore, the risk of getting infected by the influenza virus could be dramatically reduced if certain precautions are taken to decrease the chance of accidental exposure. Individuals should practice the following steps:

• Washing hands frequently for twenty seconds
• Minimize one’s contact with infected individuals
• Making certain those infected with the flu remain house bound [leaving only for medical aid]
• Coughing or sneezing into the elbow crook
• Practice social distancing by keeping at least six feet away from groups or crowded environments and staying away from areas of H1N1 infectious outbreak exposure.
• When required use a mask or respirator in the proper fashion.

Infant Feeding Considerations

Babies who are not being breast fed are at more risk of respiratory infection and are further susceptible to illness and a hospital stay than babies who are being nursed. Those women who remain influenza free should be positively reinforced to start or continue their breast feeding regimen and do so often. Under the proper conditions infants should be receiving their primary nourishment and nutritional enrichment from breast milk and so any bottle supplements should cease so babies can take in as many of their mothers antibodies as possible.

When considering H1N1 influenza and children it is thought that infants are at the most risk of all from H1N1 infection and precious little is known or understood about the infection in tiny infants. Recommendations such as only healthy adults should care for babies including feedings. Again little is known about the transmission of influenza A H1N1 virus through breast milk though reports of virus in the bloodstream for seasonal influenza is uncommon, the passing of infection into mother’s milk is likely just as infrequent an occurrence. If the possibility exists to pump milk from a virus infected mother for bottle supplementation feeding by a healthy family member, this process should be reinforced positively. It should once again be noted that generic tamiflu or relenza are not contraindicated for breast feeding.

Proper hygienic etiquette is crucial to women who are alone caring for infants while infected with influenza H1N1 virus. Ideally when ill there will be someone else available to assist with infant children. Women who are infected should also wear a facemask when feeding babies and caring for them in general to reduce the transmission of the virus.

Parents and caretakers need to be instructed on the proper methods for reducing the spread of infections like influenza A H1N1 virus which can result in respiratory complications and illness.

• Always wash hands and practice cough etiquette
• Use social distancing with children and keep them away from crowds.
• Be careful to control sharing of toys or other personal things which may have been in a child’s mouth and clean with soap and water if these items have been touched orally.
• Keep a supply of disinfectant wipes available for quick cleansing of hands or objects.

Swine Flu

The experiment was paid for and sponsored by the National Institute of Allergy and Infectious Disease [NIAID], which is affiliated with the National Institute of Health [NIH]. Health officials are concerned that the bird flu virus might produce the capability to transmit more easily from human to human and become far more deadly taking millions of lives via a flu pandemic. The point is to learn whether antiviral medications have the strength and endurance to treat and act as a prophylaxis for the avian virus since an early phase outbreak would mean few if anyone would be vaccinated. Once a vaccine becomes viable, months would be needed to produce, deliver and administer it.

Scientists who carried out the study administered one of three daily dosage amounts to the H5N1 contagious mice. The maximum amount was adjusted to the weight of the mice and was the equivalent of the expected dose for humans infected with the illness. The protocol for generic tamiflu is to take it for a course of five days, the also tested an eight day course in 50 percent of the mice. the H5N1 virus continued to spread if the medication was ceased after five days. Generic tamiflu reduces the action of the virus in the mice, inhibiting its ability to spread into uninfected cells by stopping the neuraminidase enzyme, the surface protein which enables the virus to move from infected cells to others.

There were 8-0 mice total infected with the H5N1 virus and twenty of those received a placebo drug, thirty were given tamiflu at one of those three dosage levels for a five day span, while thirty got the dose of one of three levels for an eight day period. None of the placebo group of mice lived. Just five of ten mice who were administered the top level five day dose of tamiflu survived. Oseltamivir did aid in suppressing the flu virus in the infected rodents, the virus continued to thrive if the tamiflu was discontinued after day five.
Those mice that were administered the tamiflu over eight days did do better at surviving. One of the ten mice given a low dose survived as did six of ten in the mid level range of dosage and eight out of ten that were administered the highest dosage amount survived. The eight day course of oseltamivir gave added time for the virus to decrease its levels and there was a lesser chance of the avian virus from bouncing back after the tamiflu medication dosing was closed.

On top of testing for the effective response from the tamiflu versus H5N1 flu virus in these rodents, researchers also evaluated the vigorous nature of the current avian virus from Vietnam to a 1997 strain of the same virus that caused the deaths of half a dozen individuals in Hong Kong. Scientists discovered that The recent H5N1 influenza avian virus now working its way around Vietnam is far more virulent than its previous 1997 counterpart. They are suggesting that a longer phase of tamiflu antiviral medication will likely be necessary to defeat the ferociousness of the antigenic version of the H5N1 bird flu virus.

They believe that H5N1 is going through a quickening redevelopment phase that is tenacious. Experts were taken back by the persistence of this strain of bird flu. This initial study will be useful when future research is conducted by offering up a basis for measurement towards treatment and prevention of the avian virus utilizing oseltamivir – tamiflu antiviral medication.

After a spinal tap procedure on a young Vietnamese victim of influenza H5N1 performed in England physicians found traces of H5N1 in the boy’s spinal fluid which indicates this flu virus has the capability to transmit to the brain. More science is required to determine whether higher doses of tamiflu over a longer course can thwart H5N1 from entering the lungs and establishing a grip so it can then spread to the brain. Animal study models using avian flu virus to closely mimic the illness in a person are planned.

The NIAID is a section of the National Institute of Health connected with the United States Department of Health and Human Services and the NIAID is supportive of basic and practical research in order to diagnose, treat and prevent infectious communicable diseases like influenza, among others.

Bird Flu

A recent study that was carried out found that it was safe and well tolerated in children who had asthma. This is important because asthmatic children can have problems when taking many kinds of drugs. Having a drug that can help against the potentially very harmful effects of flu is therefore important. The same study found that tend rug actually helped to improve an asthmatic child’s lung function, and decreased the effects of an asthma attack. In addition, the drug was found to help decrease the duration of a flu attack.

Some parents have reported an almost instantaneous improvement in their child’s health once they have taken Tamiflu. This is of course not impossibility, but it is not generally the norm in children. On the other hand, some parents report that once Tamiflu is taken, nothing happens in the way of beneficial health in their children. It is not a mystery why this is the case when you consider that one must take Tamiflu within 48 hours of the first influenza symptoms appearing. With many parents not being able to recognise flu symptoms straight away, one can see why this skewed perception of the drug’s effectiveness can happen.

Many people have complete faith in Tamiflu, and believe that it has a genuine positive effect the health f their children and their family as a whole. If a child takes Tamiflu and is around someone who has the flu, it is generally viewed that, in the best case scenario, they never develop symptoms. And if they do, then the symptoms will not be as severe as they could be.

There are some issues as regards Tamiflu. Some people view the cost of the drug to be quite prohibitive, for example. For such a world beater f a drug, it is not difficult to see why it does cost a lot to manufacture and distribute.

The fruit flavour Tamiflu suspension version is actually quite unpleasant for children to take. Anyone who has children and has trued to give them medicine that does not taste nice will understand the problems that come with that issue.

Also, may people feel that the side effects of Tamiflu can make it an unattractive drug to have to consider. No one likes unpleasant side effects, and some people believe the side effects of the Tamiflu drug to be more unpleasant than those suffered with other drugs.

As with most drugs, the side effects with Tamiflu are not common among all takers of the substance. However, they have been reported among enough people to make them worth considering. Vomiting is one of the side effects that have been reported among patients who have taken the drug. This can of course be particularly unpleasant, especially if it is suffered by children. However, if you feel that it is too unpleasant to bear, consult with your doctor, who may be able to offer some kind of respite from the vomiting, or advise on dosage levels.

Stomach pain can also be an issue. However, this, like any other side effect that is linked to any other drug, is not a common occurrence. Possibly quite unpleasant if suffered, your physician should be able to advise you on any relief that you can get for this complaint. If symptoms persist, again the physician may advise of a different dosage of the drug, or even advise that you stop taking the dug altogether.

There have been reports of potentially more serious side effects that have been suffered. These took place in only some areas of the world, and included some hallucinatory episodes suffered by users of the drug. Again, these side effects are very rare, and your physician can keep monitoring your heath while you are taking Tamiflu, to support if any such unpleasantness occurs.

Tamiflu is a very effective drug against the influenza virus. Side effects are rare, as with most drugs, and the beneficial effects, especially on the health of children, are considerable.

Tamiflu

Included in this increase where previously excluded pediatric groups and those other people or groups who did not figure in the original parameters for receiving the drug as a preventative medicine. The influenza virus can cause serious complications and even death in those patients with seriously compromised immune systems. This would include HIV patients [infected toddlers and infants specifically] and young kids.

The antiviral medication oseltamivir [or tamiflu] has been accepted as a treatment and preventative therapy for influenza virus in patients who are one year or older. Its medicinal counterpart Relenza has been approved for treating serious but uncomplicated illness due to influenza contagion within adults and kids seven years and upwards. They must be indicative of the flu for less than a two day period and may also be treated as a therapeutic prevention drug in adults and children over five years of age.

The Emergency Use Authorization for tamiflu means tamiflu may also be utilized as a treatment and preventative drug in babies under one year old, and also to give optional dosage proposals for kids older than one year of age. As well, based on these EUA’s, both antiviral drugs can also be dispensed to bigger sub sections of society without the need to obey the instructions for the meds based on labeling which otherwise would be the case and provide written description of the emergency utilization. The drugs can also be dispensed by a larger segment of health care providers such as health officials and volunteers as allowed by state and regional laws or health service crisis reactions.

The Emergency Use Authorization though only temporary includes the following broader provisional policies, which are to expire when the emergency is ended:

• Tamiflu can be used as a treatment as well as a preventative therapy for infants under one year of age. As of now, tamiflu can be used on children one year or older. The new options for infants under one year were decided upon after review of safety and pharmacokinetics trials data by manufacturer Roche and the Collaborative Antiviral Study Group NIAID/NIH [National Institute of Allergies and Infectious Disease – National Institute of Health]. Also age appropriate dosage options in older kids formed part of the new proposal. These new EUA options are for the oral use of tamiflu and are as follows:
• Extended EUA tamiflu dosage options for treating influenza in patients with body weight [in kg] body weight [in lbs] dosage by age treatment doses for five days.
• Over 40 kg – over 88 lbs over 10 yrs 75 mg twice a day
• Over 23 kg to 40 kg over 51 lbs to 88 lbs 6 – 9 yrs 60 mg twice a day
• Over 15 kg to 23 kg over 33 lbs to 51 lbs 3 – 5 yrs 45 mg twice a day
• Under 15 kg under 33 lbs 1-2 yrs 30 mg twice a day
• Dosing for Babies younger than one year
• Not considered by weight 6 – 11 months 25 mg twice a day
• 3 – 5 months 20 mg twice a day
• Under 3 months 12 mg twice a day

The bottle dispenser for tamiflu oral suspension medicine is marked of in gram measurements and is available for children weighing more than 40 kg or adults who have a difficult time swallowing pills. Dosages are measured as follows for heavier/older children and adults – 30 mg’s measured followed up by 45 mg measured. For babies under one year a different type of measuring tool needs to be used which can discharge 2 ml [roughly 25 mg], 1.6 ml [approx. 20 mg], or 1 ml [or 12 mg].

Dosages for the current swine flu or H1N1 are equal for each age group however; doses are only given once each day instead of twice a day. When administering preventative dosages they should be consumed for a ten day course after contact with an infected individual or in the event of a localized outbreak.

Utilizing Tamiflu and Relenza for those patients excluded from current labeling instructions. Both medications are presently cited for use on patients showing heightened but uncomplicated influenza and the symptoms have been present for under forty eight hours. This EUA calls for utilization of tamiflu and Relenza in more severely infectious persons or those who have displayed symptoms for more than the forty eight hour time period. This is based on research data and the latest understanding of how H1N1 influenza reacts with different appearances. After considering patient susceptibility and the availability of these antivirals, physicians or health care providers can make an individual risk reward appraisal concerning how best to use these products.

Tamiflu

In November 2005, Then president George W. Bush asked Congress for funds totaling 7.1 billion USD for emergency financial support for a flu pandemic awareness and preparation plan [this on top of a bill passed by the senate for 8.1 billion USD]. Included in the Bush program was a desire to purchase 1.4 billion dollars worth of government purchased antiviral medications.

What Happens When Oseltamivir Is Stockpiled?

With oseltamivir in short supply, many people began to stockpile the medication in the event of an outbreak. A number of American states issued declarations, which in no uncertain terms discouraged people from doing this. Of late, the manufacture of tamiflu seems to have finally leveled off according to demand. This means many of the issues accompanying stockpiling have been diverted somewhat. The problem has only been weigh laid and if a pandemic once again looms, lowered supply will again become a problem.

It has been argued in medical journals that when personal stores of these medications are used the risk of resistant strains of the virus could become reality if lower dosages are utilized. Current guidelines provide only ten – 75 mg capsules as a recommended dosage and this may prove to be inadequate in a breakout.
Another reason not to store drugs is the tactical administration of the medications to first responders or critical care personnel should come first. Hardest hit population centers also require crisis management of meds because of vulnerability leading to easier spread of the virus and those folks who actually are hit with a flu virus. There have been arguments about the moral reasoning behind wealthier populations or countries receiving preferential access to drugs. When stockpiling occurs, the drugs may be diverted from poorer destinations in order to compensate and the poor countries are likely harder hit by infection. In that same vein, it is difficult to condemn personal stockpiling when corporate warehousing of these drugs is so prevalent and even encouraged.

A further dispute says that home use of tamiflu would make it trickier to establish whether or not a prescription is imitation or not. There is real uncertainty with this issue but in the event of an outbreak, people may go ahead with their purchase regardless. In late 2005, some fifty three parcels of fake tamiflu pills were seized by US Customs agents in San Francisco. These packs displayed Generic Tamiflu on the wrapper. Roche personnel can speak of only a single instance of bogus tamiflu surfacing outside the U.S – there were inaccurately labeled pills discovered in Holland that were only vitamin C and lactose. The concern is that high brow unlawful distributors could easily make genuine looking wrapping down the road.

A final issue regarding warehousing of drugs is that Viruses are only diagnosed in a minimal number of laboratories globally; hence, how are those with personal stockpiles going to determine if symptoms being felt are those of an influenza strain or some other less threatening condition. The problem with this argument is that treatments should already be started by the time a diagnosis is made from any lab.

A dispute favoring personal warehousing stems from manufacturer Roche saying for the record that if more shipments weren’t soon received they could be forced to in fact, restrict their production of tamiflu. Personal stockpiling would bring the market to bear at this point, continuing manufacturing levels that would allow for entire on hand supply to climb in case orders once again surpass manufacturing potential, something such as an influenza pandemic or outbreak.

Tamiflu

Tamiflu is a recognised and extremely powerful antiviral drug that can be used to treat the flu virus. It can be used proactively, but its effect here is limited. However, it has proven very effective in reducing the effects and duration of a viral infection.

Tamiflu is approved for the use of adults and children over the age of twelve. Anyone under this age should not take Tamiflu. This is absolutely essential as a dosage requirement. In any case, Tamiflu is a prescription drug; hence there should be very little chance of someone taking it if they are not supposed to. Bearing this is mind, if you know of anyone under the age of twelve who is taking or who is exposed to Tamiflu, stop them immediately, and seek medical advice.

The drug is also not approved for any women who are pregnant or nursing. Again, the negative effect that can arise if a pregnant or nursing woman takes the drug can be considerable. With a pregnant or nursing woman, the drug can have an adverse effect on the health of the baby or infant.

In addition, another patient group who should not be exposed to Tamiflu are those who are allergic to Oseltamivir Phospate, which is the main ingredient in Tamiflu. Because the drug is available on prescription, your physician should be able to advise if you are allergic to this particular substance.

When it comes to those people who have more serious medical conditions, their physician will make the decision as to whether or not Tamiflu is right for them. People with any kind of kidney problem, for example, can face medical issues if they take Tamiflu. The physician will advise on whether or not that person should take the drug. The same applies to anyone who has a respiratory problem or disease or in fact any kind of serious health problem that can cause drugs to be reduced in effectiveness or to interact in a negative way. All of these issues can be resolved with the physician, and may or may not result in the drug being approved for use.

You can take Tamiflu mainly to treat the flu. It is not generally seen as something that can cure the flu. However, some physicians may prescribe to help the body protect against an impending or current strain of the flu virus. If this is the case, they may say that it is a preventative measure. If this is what the physician says to you, bear in mind that the drug may help against the symptoms, or at least their severity, but it is not used as a cure for the flu. In other words, you will not see an instant improvement.

General dosages follow the pattern of the patient taking one dosage in the morning of the drug in tablet form. Then taking one capsule of the drug in the evening is the norm. This continues for five days if the drug has been prescribed as a treatment for the symptoms of flu. However, if the drug has been prescribed as a preventative treatment, then the dosage does change a little. It is in this kind of case that the doctor may state that you take one capsule per day for ten days. If there is an outbreak of flu in the community, the doctor may suggest that you take Tamiflu for up to six weeks. Again, this is not a cure, but instead a proactive treatment against the symptoms of the flu.

Tamiflu has been known to have some side effects, such as mild to moderate vomiting. If you take the drug with food or milk these symptoms may decrease to the extent that they feel less troublesome. Again, your doctor will advise.

These are the basic facts about Tamiflu. Remember that your doctor will advise on all aspects of taking the drug when they prescribe it to you.

Tamiflu

When antivirals gain extensive use a resistance is built up against them, as was the case with some previous antivirals prior to oseltamivir. The same was expected of tamiflu but in a less recurrent manner than antivirals such as amantadine or rimantadine. Resistance statistics for tamiflu up until July, 2004 based on clinical studies was 0.33% in adults and 4.0% in kids, 1.26% on whole. Mutations, which aid resistance, are lone amino acid residue substitutions in the neuraminidase enzyme.

Information published recently has strongly recommended that antivirals stocks of tamiflu [oseltamivir] be supplemented with more antivirals such as zanamivir [aka Relenza] because of studies done on this type of medication and results of the seasonal influenza and its mutated resistance to tamiflu stocks. This warning is based on the theory that the new 2009 H1N1 swine flu virus could suffer the same resistance pattern.

Research showed that the influenza A virus mutated and resistance to tamiflu was evident. The stats showed a group of fifty children treated oseltamivir and eighteen percent proved resistant to the drug. Another test showed similar numbers when a group of Japanese child counterparts infected with H1N1 influenza found 16.3 percent resistant. The rationale by researchers was simply twofold. Children tend to suffer their infections for longer spans thus leaving more time for virus mutation leading to resistance and that current detection capabilities have become more thorough than in prior studies. Elevated resistance levels were discovered in a young girl in South east Asia undergoing oseltamivir treatment for Avian influenza H5N1 virus.

Further, multiple findings of resistance in these areas of patients with H5N1 flu virus also showed resistance developing. Medical professionals again rationalized that this could be a result of patient’s declining medical conditions. They also speculated that dosage amounts prescribed of oseltamivir for influenza sometimes are not potent enough to thwart the reproduction of the virus thus enabling the replication process and mutated strains. Medical experts agree that personal stockpiling of antivirals such as tamiflu may inevitably pave the way to lower dosages and the unintended appearance of resistant varieties of H5N1 Avian influenza.

Of course the larger concern is an influenza pandemic developing and in the case of H5N1 may seem more likely due to the length of time newer infectious viruses such as the avian seem to last. The result of this longer active period for newer strains is that resistance should be anticipated in the event of a pandemic.

It should be noted that mutated viruses, which develop resistance to antivirals such as oseltamivir, tend to lose strength or become impaired due to the stress placed on the enzyme during mutation at the genetic level making it less efficient. The advantage to antivirals such as oseltamivir and as well as zanamivir is that they are broad spectrum medications and they each target the enzyme of various flu strains. In addition, the growth of a vibrant and resistant flu type does not seem at all inevitable. Also important to note that the resistance found in the child studies for oseltamivir showed that the resistance appeared individually in the kids and was not passed via human contact or with avian contact.

2007 had Japanese health experts discovering neuraminidase-resistant Influenza B illness varieties in people that were not treated with these antiviral medications, stats showed an incidence occur rate of 1.7 percent. In 2008 the WHO [World Health Organization] declared that the early outcome from testing of Canadian influenza A virus, subtype H1N1 illustrated that eight out of eighty one samples proved to be resistant to oseltamivir. There have been resistant varieties appearing in the European Union that are still susceptible to zanamivir.

The Center for Disease Control [or CDC] states that tamiflu may prove unable to combat influenza type A, the most prevalent variety around in 2008. Warnings are being distributed to health care providers to be on the lookout for this strain so they can make every effort to fight the virus by other means if tamiflu fails.

Tamiflu

Once generic tamiflu is consumed orally, it is absorbed into the body by the gastrointestinal tract. The drug is converted to an active metabolite in the liver, and then it is distributed throughout the body and particularly in the upper and lower respiratory tract. Oseltamivir prevents the spread of the infection within the airway passages and the lungs. Its maximum effectiveness is reached 3 to 4 hours after consumption.
When testing children who had taken generic tamiflu, they were found to recover from the flu illness up to 26% faster than those who did not take the drug. In adults, their recovery time was shortened up to 30%, or by an average of 1.3 days.

Oseltamivir should be taken at the same time each day so the amount of medication in your body remains at a constant level throughout the day. It is available in strengths of 30 mg, 45 mg, and 75 mg capsules or in a liquid form with 12 mg per ml. The typical adult dosage is 75 mg taken twice daily for a period of five days as a treatment for flu. When taken as a preventative measure, the usual dose in individuals over 13 years of age is 75 mg taken once daily, and it can be safely taken for up to six weeks.

You should store generic tamiflu at room temperature and away from moisture. When the liquid form of this medication is dispensed by a pharmacist, it should be discarded after 10 days.

Once you start taking generic tamiflu, you need to take the entire prescription until it is finished. If you stop the medicine because you begin to feel better but the prescription is not finished, the symptoms may return.
If you happen to take an overdose of oseltamivir, you need to seek immediate medical attention. Possible reactions include nausea and vomiting. However, if you miss a dose, then take the prescribed amount as soon as you remember. If it is close to your next scheduled dosage time, then it is okay to miss a dose and just take your regular dose. Never take a double dose of Oseltamivir in order to compensate for a missed dose.

Side effects are not common, but some people experience nausea, vomiting, and diarrhea, when taking generic tamiflu. These symptoms usually occur within the first few days when taking the medication, and are classified as either mild or moderate. If you take food along with the oseltamivir, this may help to alleviate these side effects.

Some people experience skin rashes and allergic reactions and a doctor should be consulted if these side effects occur. Other reactions include difficulties breathing, swelling of the tongue or lips, swelling of the face, and constriction of the throat. If you experience any of these reactions, stop taking the medication immediately and go to the nearest emergency room as serious complications may occur.

Children and adolescents who are taking oseltamivir as a treatment for the flu may experience confusion, hallucinations, speech problems, anxiety, nightmares, or unusual behavior including self-injury. If this reaction occurs, a medical practitioner should be contacted immediately.

Other known side effects include difficulties sleeping, abdominal pain, bronchitis, headache, seizures, aggravation of diabetes, and dizziness.

Generic tamiflu is not recommended for women who are pregnant or nursing, as the effect on the baby is unknown. If you become pregnant while taking this medication, notify your doctor immediately. You should also notify your doctor of any other medications you are taking, including both prescription and non-prescription medications. This also includes any herbal remedies, vitamins, minerals, and dietary or nutritional supplements.

Generic tamiflu is not recommended for those who have or have had kidney disease or any condition that causes swelling of the brain. Notify your doctor if you have ever had any diseases that affect the immune system such as HIV or AIDS, or if you have heart, liver, lung or kidney diseases. Also, tell your doctor if you have received a nasally administered influenza vaccine within 2 weeks of treatment so side effects are avoided.

Tamiflu